Cannabis Amendments

Creates a new medical cannabis ombudsman position to handle appeals and provide training to citizens and groups about the medical cannabis program.

Establishes a new medical cannabis pharmacy license specifically for independent medical cannabis pharmacies with ownership restrictions.

Increases the maximum number of cannabis cultivation facility licenses from 8 to 15 under certain conditions.

Limits cannabis processing facility licenses to a maximum of 18.

Changes pharmacy ownership limits to 30% of total medical cannabis pharmacy licenses issued by the department.

Allows cannabis processing facilities to maintain websites with product information if age verification mechanisms are in place.

Repeals the state central patient portal and related sections, replacing them with new ombudsman duties.

Requires medical cannabis pharmacies to provide patient product information inserts to patients purchasing medical cannabis products.

Allows home delivery medical cannabis pharmacies to operate closed-door locations with specific security and supervision requirements.

Modifies enforcement provisions including fine amounts and procedures for administrative citations and seizures.

Adds new definitions for terms including 'antcompetitive business practice,' 'artificially derived cannabinoid,' 'closed-door medical cannabis pharmacy,' and 'patient product information insert.'

Moves the repeal of the Cannabis Research Review Board from July 1, 2026 to July 1, 2025.

Extends the repeal date for the Medical Cannabis Governance Structure Working Group from July 1, 2025 to July 1, 2026.

Created a new medical cannabis ombudsman position to handle appeals and review proposed rules.

Established a medical cannabis sales website where processing facilities can list products and pharmacies can fulfill orders.

Increased testing requirements for cannabis products, including terpene profiling and additional toxin testing.

Required medical cannabis pharmacies to provide patient product information inserts with purchase.

Modified closed-door pharmacy rules to limit the number of licenses and set revenue caps.

Added pharmacy ownership limits to prevent excessive concentration of pharmacy licenses.

Changed enforcement procedures to require a letter of concern before other administrative actions, except for public health threats.

Adjusted repeal dates for the Cannabis Research Review Board and Medical Cannabis Governance Structure Working Group.

Extended the deadline for issuing closed-door pharmacy licenses to July 1, 2027.

Updated definitions to include terms like 'artificially derived cannabinoid' and expanded advertising restrictions.

Created a new medical cannabis ombudsman position within the Department of Commerce to handle complaints, review proposed rules, and assist patients with financial assistance.

Established a new medical cannabis pharmacy license category for independent pharmacies with specific ownership restrictions and operational requirements.

Increased the maximum number of cannabis cultivation facility licenses from 8 to 15, and limited cannabis processing facility licenses to a maximum of 18.

Required cannabis processing facilities to maintain a website displaying product certificates of analysis and created a new medical cannabis sales website for product transparency.

Required medical cannabis pharmacies to provide patient product information inserts to customers and display product back panel images on their websites starting July 1, 2025.

Created a new medical cannabis ombudsman program providing monthly $150 vouchers to Medicaid/Medicare patients for medical cannabis costs.

Extended the repeal date for the Medical Cannabis Governance Structure Working Group from July 1, 2025 to July 1, 2026.

Added new definitions for 'independent medical cannabis pharmacy,' 'closed-door medical cannabis pharmacy,' and 'patient product information insert.'

Modified enforcement procedures to require ombudsman review before certain administrative penalties can be issued, adding a 10-day dispute resolution window.

Added pharmacy ownership limits, restricting ownership to 30% of total medical cannabis pharmacy licenses issued by the department.

Creates a new medical cannabis pharmacy license for independent pharmacies with ownership restrictions to prevent market consolidation.

Establishes a medical cannabis ombudsman to handle patient complaints, review proposed rules, and provide assistance for patients unable to afford treatment.

Allows cannabis processing facilities to maintain websites with product information and limits the number of cultivation facility licenses to 15 total.

Requires medical cannabis pharmacies to provide patient product information inserts and display product back panels on their websites.

Creates a medical cannabis sales website where processing facilities can list products and pharmacies can fulfill orders.

Moves the repeal of the Cannabis Research Review Board to July 1, 2026, and extends the repeal of the Medical Cannabis Governance Structure Working Group to July 1, 2026.

Modifies enforcement procedures for pharmacies and couriers, including appeal processes handled by the ombudsman for certain penalties.

Adds definitions for new terms including 'independent cannabis testing laboratory,' 'medical cannabis ombudsman,' and 'targeted marketing.'